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Modelling
A standard decision tree was used to represent the patient pathway from the point of identifying individuals for testing to the offer of treatment with antiviral therapy. Then, a Markov model was developed to simulate the progression of hepatitis C in a hypothetical cohort of 10,000 eligible individuals. The time horizon of the model was lifetime (the average age of a typical patient was 37 years). The health states, cycle length and transition probabilities were reported in full.
Sources searched to identify primary studies
Data on the prevalence of HCV in the population strategy were derived from an unpublished source. This represented the only available UK estimate and was obtained through contact with experts. The prevalence of HCV in the targeted strategy was obtained from a published UK study. Other epidemiological data were obtained from UK databases. Test accuracy came from manufacturer's data (PCR) or a systematic review of the literature and meta-analysis (ELISA). Data on the treatment effect for antiviral therapies were obtained from randomised controlled trials (RCTs) or reviews of RCTs. Other published and unpublished sources were used to derive data on mortality, acceptance of tests and transition probabilities for disease progression. In general, UK estimates were used to populate the model.
Methods used to judge relevance and validity, and for extracting data
A review of the literature was undertaken. Commonly used databases (MEDLINE, EMBASE, the Cochrane Library and NHS EED) were searched to identify relevant studies from 1996 to 2004. Researchers and clinicians were also contacted. Only English language literature was searched. It would appear that the most recent and robust estimates were chosen from amongst those found in the literature. In particular, the authors stated that sources for clinical data were chosen on the basis of the methodological quality, publication date (favouring the most recent studies), relevance to the UK and appropriateness of the sample size. Given the lack of published evidence, some data were based on personal communications and expert opinion.
